Listen to the article
An experimental medication derived from nitazenes has demonstrated powerful pain relief without the dangerous side effects typically associated with opioids, according to recent research from the National Institute on Drug Abuse (NIDA).
The study, published in the journal Nature, focused on a derivative called DFNZ, which provided at least two hours of pain relief in mice within just five to ten minutes of reaching the brain. Unlike traditional opioids, the compound showed no signs of respiratory depression, addiction potential, or significant withdrawal effects.
“Nitazenes are a dangerous group of drugs that have no medical indication and are highly addictive,” explained Dr. Marc Siegel, Fox News senior medical analyst. “They can be hundreds or thousands of times more potent than morphine.”
Nitazenes were originally developed in the 1950s as potential pain relievers but were abandoned due to their high addiction risk and overdose potential. They have since become problematic drugs in the illicit market. However, researchers saw potential in modifying their chemical structure to create safer alternatives.
“We wanted to decrease the potency and create a potential therapeutic,” said Michael Michaelides, PhD, senior author of the study and NIDA investigator. “What we discovered exceeded our expectations.”
Traditional opioid medications, while effective for pain management, come with serious risks. They can cause respiratory depression—dangerously slow or shallow breathing that leads to carbon dioxide buildup and decreased oxygen levels. They are also associated with increasing tolerance, severe withdrawal symptoms, and high addiction potential.
“Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose,” noted Nora D. Volkow, MD, director of NIH’s National Institute on Drug Abuse. “Developing a highly effective pain medication without these drawbacks would have enormous public health benefits.”
What makes DFNZ particularly promising is its unique pharmacological profile. Rather than depressing respiration, the compound was found to moderately increase brain oxygen levels. The researchers reported that repeated doses did not result in tolerance, drug dependency, or meaningful withdrawal effects. The only classic opioid withdrawal symptom observed was mild irritability.
“DFNZ has an unprecedented pharmacology for an opioid,” said Michaelides. “It is a potent and high-efficacy analgesic, but in certain contexts it resembles partial agonists, drugs that activate the receptor with low efficacy, which is what scientists think is needed for safety.”
Another distinctive feature of DFNZ is how it affects the brain’s reward system. According to Dr. Siegel, “It releases dopamine more gradually, which is safer” than the rapid dopamine release caused by traditional opioids—a mechanism that contributes to their addictive properties.
The discovery comes amid America’s ongoing opioid crisis, which has claimed hundreds of thousands of lives over the past two decades. Developing safer alternatives to current pain medications could significantly impact public health by providing effective pain relief without contributing to addiction and overdose deaths.
The research team envisions multiple potential applications for DFNZ, including treatment for opioid use disorder, post-surgical pain management, and relief for cancer-related or chronic pain. However, they caution that more research is needed before human trials can begin.
“There’s a lesson here – that even a dangerous chemical can lead to a potential treatment,” noted Dr. Siegel. “This needs to be tested in humans, but I think there is potential for a much safer pain drug that is not only not addictive, but may also be a potential treatment for addiction.”
Medical experts not involved in the study urge caution when interpreting the early results. Dr. Hooman Melamed, a board-certified orthopedic spine surgeon in Beverly Hills, highlighted several concerns about the preliminary findings.
“This new drug claims to release a lower-dose opioid alternative that might be able to offer pain relief without the addictive properties,” Melamed said. “It’s also important to note that this has not been tested on humans, and we don’t know how this will impact people in the long run.”
He also pointed out the “very narrow therapeutic threshold” often associated with opioid drugs. “A small increase in the dosage could become addictive for people, and without solid human data, we just can’t know the dependency risk,” Melamed explained.
Additional concerns include potential impacts on digestive health, as many opioids slow intestinal mobility, leading to issues like constipation and impaired digestion. Long-term cognitive effects also remain unknown.
The research team plans to conduct more preclinical studies before seeking regulatory approval for human clinical trials—a process that could take several years but holds promise for addressing one of medicine’s most challenging dilemmas: providing effective pain relief without the devastating consequences of addiction.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
10 Comments
While the initial results for this new opioid derivative sound promising, I remain somewhat skeptical. We’ve seen similar claims before, only for new drugs to later be found to have unforeseen addiction risks or other serious side effects.
I hope the researchers can truly crack the code and develop a safe, non-addictive opioid alternative, but the bar is high given the history of the opioid epidemic.
This is certainly an intriguing development in the search for non-addictive pain relief. The ability to provide powerful analgesia without the respiratory depression and withdrawal effects of traditional opioids would be a major breakthrough. However, the proof will be in the longer-term clinical data.
I’m curious to learn more about the specific chemical modifications made to the nitazene structure and how they were able to achieve the desired effects.
This is an interesting development in the ongoing search for safer pain relief options. Modifying the chemical structure of nitazenes to reduce their potency and addictive potential could be a promising approach, if the early results hold up in further testing.
I’m curious to see how this experimental opioid compares to other non-addictive pain relief alternatives like cannabinoids or non-opioid receptor agonists.
I appreciate the researchers’ efforts to find a safer alternative to the highly potent and addictive nitazene opioids. The prospect of powerful pain relief without the risk of respiratory depression or addiction is certainly compelling.
It will be important to closely monitor the long-term effects and potential for misuse if this experimental opioid makes it to market.
The fact that this new compound provided pain relief without the dangerous side effects of traditional opioids is certainly encouraging. However, it’s important to remain cautious until we see more data from clinical trials on its efficacy and safety.
Given the devastating opioid crisis, any non-addictive pain relief option that could potentially replace traditional opioids would be a major breakthrough.